Quince Therapeutics (NASDAQ:QNCX) Now Covered by Analysts at Maxim Group

Research analysts at Maxim Group assumed coverage on shares of Quince Therapeutics (NASDAQ:QNCX - Get Free Report) in a note issued to investors on Thursday,Benzinga reports. The brokerage set a "buy" rating and a $6.00 price target on the stock. Maxim Group's price target indicates a potential upside of 297.35% from the stock's current price.

A number of other brokerages have also recently weighed in on QNCX. Rodman & Renshaw started coverage on shares of Quince Therapeutics in a research report on Tuesday, October 29th. They set a "buy" rating and a $11.00 price target on the stock. EF Hutton Acquisition Co. I upgraded Quince Therapeutics to a "strong-buy" rating in a report on Tuesday, October 22nd. Finally, RODMAN&RENSHAW raised Quince Therapeutics to a "strong-buy" rating in a research note on Tuesday, October 29th.

Quince Therapeutics Trading Up 3.4 %

NASDAQ:QNCX traded up $0.05 during mid-day trading on Thursday, hitting $1.51. The company's stock had a trading volume of 209,106 shares, compared to its average volume of 222,060. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.15 and a current ratio of 6.15. Quince Therapeutics has a fifty-two week low of $0.51 and a fifty-two week high of $1.79. The stock has a fifty day moving average of $0.87 and a 200-day moving average of $0.82.

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter.

Insider Activity

In other Quince Therapeutics news, CEO Dirk Thye purchased 77,500 shares of the business's stock in a transaction on Thursday, August 29th. The shares were purchased at an average cost of $0.69 per share, with a total value of $53,475.00. Following the transaction, the chief executive officer now directly owns 766,941 shares of the company's stock, valued at $529,189.29. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Quince Therapeutics news, President Charles S. Ryan bought 48,387 shares of the stock in a transaction dated Tuesday, August 20th. The shares were bought at an average cost of $0.65 per share, with a total value of $31,451.55. Following the completion of the acquisition, the president now owns 122,461 shares of the company's stock, valued at $79,599.65. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Dirk Thye bought 77,500 shares of the business's stock in a transaction on Thursday, August 29th. The stock was bought at an average price of $0.69 per share, for a total transaction of $53,475.00. Following the transaction, the chief executive officer now directly owns 766,941 shares of the company's stock, valued at approximately $529,189.29. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 158,887 shares of company stock worth $105,609 over the last ninety days. Insiders own 16.80% of the company's stock.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.